Kidney Res Clin Pract.
2020 Jun;39(2):180-191. 10.23876/j.krcp.20.016.
Reduced risk for chronic kidney disease after recovery from metabolic syndrome: A nationwide populationbased study
- Park S
1,2 - Lee S3,4
- Kim Y5
- Lee Y3,4
- Kang MW3,4
- Han K6
- Lee H3
- Lee JP4,7,8
- Joo KW3,4,7
- Lim CS4,7,8
- Kim YS1,3,4,7
- Kim DK3,4,7
- Affiliations
-
- 1Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
- 2Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Republic of Korea
- 3Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
- 4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
- 5Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea
- 6Department of Medical Statistics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
- 7Kidney Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
- 8Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea
- KMID: 2503867
- DOI: http://doi.org/10.23876/j.krcp.20.016
Abstract
- Background
Metabolic syndrome (MetS) is linked to various chronic comorbidities, including chronic kidney disease (CKD). However, few large studies have addressed whether recovery from MetS is associated with reduction in the risks of such comorbidities.
Methods
This nationwide population-based study in Korea screened 10,664,268 people who received national health screening ≥ 3 times between 2012 and 2016. Those with a history of major cardiovascular events or preexisting CKD were excluded. We classified study groups into four, according to the course of MetS state, as defined by the harmonizing criteria. The main study outcome was incidental CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m2 which was persistent until the last health exams). The study outcomes were investigated using multivariable logistic regression analysis, which was adjusted for clinical variables and the previous severity of MetS.
Results
Four study groups included 6,315,301 subjects: 4,537,869 people without MetS, 1,034,605 with chronic MetS, 438,287 who developed MetS, and 304,540 who recovered from preexisting MetS. Those who developed MetS demonstrated higher risk of CKD (adjusted odds ratio [OR], 1.26 [1.23-1.29]) than did those who did not develop MetS. In contrast, MetSrecovery was associated with decreased risk of CKD (adjusted OR, 0.84 [0.82-0.86]) than that in people with chronic MetS. Among the MetS components, change in hypertension was associated with the largest difference in CKD risk.
Conclusion
Reducing or preventing MetS may reduce the burden of CKD on a population-scale. Clinicians should consider the clinical importance of altering MetS status for risk of CKD.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Prevalence of Metabolic Syndrome inthe Chronic Kidney Disease Patients
- Metabolically Healthy Obesity: Epidemiology, Criteria, and Implications in Chronic Kidney Disease
- Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- Can management of the components of metabolic syndrome modify the course of chronic kidney disease?
- Clinical impact of nonalcoholic fatty liver disease on other medical diseases
